Risperidone: An assessment of its economic benefits in the treatment of schizophrenia

References

• Kane, JM, Freeman, HL, Towards more effective antipsychotic treatment. British Journal of Psychiatry, 1994. 165(Suppl 25): 22–31.
   Google Scholar
• Knapp, M, Kavanagh, S, Economic Outcomes and Costs in the Treatment of Schizophrenia. Clinical Therapeutics, 1997’. 19(1): 128–138.
   Google Scholar
• Williams, R, Dickson, RA, Economics of Schizophrenia. Canadian Journal of Psychiatry, 1995. 40(7 Suppl 2): S60-67.
   Google Scholar
• UK Clinical Standards Advisory Group, Schizophrenia Volume 1, August 1995.
   Google Scholar
• Glennie, JL, Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia, 1997, Canadian Coordinating Centre for Health Technology Assessment (CCOHTA): Ottawa, Ontario.
   Google Scholar
• Chew, R, Compendium of Health Statistics, 1995, Office of Health Economics, London.
   Google Scholar
• Kerwin, RW, An essay on the use of new antipsychotics. Psychiatric Bulletin, 1996. 20: 23–26.
   Google Scholar
• Viale, GL, Evaluating the cost effectiveness of newer psychotropic medications. American Journal of Managed Care, 1997’. 3: S7 - S10.
   PubMedGoogle Scholar
• Schatzberg, A, Nemeroff, C, eds. Textbook of Psychopharmacology. 1995, American Psychiatric Press: Washington DC.
   Google Scholar
• Weiden, PJ, Olfson, M, Cost of relapse in schizophrenia. Schizophrenia Bulletin, 1995. 21(3): 419 – 429.
   PubMed Web of Science ®Google Scholar
• Shepherd, M, Watt, D, Falloon, I, et al., The natural history of schizophrenia. A five year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychological Medicine, 1989(Monograph Supplement 15): 1–46.
   Google Scholar
• Mason, P, Wild, D, Cookson, RF, et al., Measuring quality of life in people with schizophrenia. British Journal of Psychiatry (submitted), 1998.
   Google Scholar
• Awad, AG, Voruganti, LNP, Heslegrave, RJ, Measuring quality of life in patients with schizophrenia. Pharmacoeconomics, 1997’. 11(1): 32–47.
   Google Scholar
• Franz, M, Lis, S, Pluddemann, K, et al., Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. British Journal of Psychiatry, 1997’. 170: 422–425.
   Google Scholar
• Glazer, WM, The impact of managed care systems on relapse prevention and quality of life for patients with schizophrenia. European Neuropsychopharmacology,1996. 6(S2): 35–39.
   Google Scholar
• Bosanquet, N, Schizophrenia: developing new strategies for effective care. British Journal of Medical Economics, 1995. 8: 51–64.
   Google Scholar
• Soumerai, SB, McLaughlin, TJ, Ross-Degnan, D, et al., Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine, 1994. 331: 650–5.
   Google Scholar
• Chisholm, D, Healey, A, Knapp, M, QALYs and mental health care. Mental Health Research Review, 1995. 2: 17 – 19.
   Google Scholar
• Eli Lilly and Company Limited, Olanzapine Product Monograph, 1996: Basingstoke UK.
   Google Scholar
• Wirshing WC and Marder SR, Efficacy and dosing issues of novel antipsychotics. Int J Psychiatry in Clinical Practice, 1998 (2): S35-S38; Farde L and Nyberg S, Dosing determination for novel antipsychotics: a PET based approach. Int J Psychiatry in Clinical Practice, 1998 (2): S39-S42
   Google Scholar
• Lieberman, JA, Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. Journal of Clinical Psychiatry, 1996. 57(Suppl 11): 68–71.
   Google Scholar
• Goldberg, D, Cost-effectiveness studies in the treatment of schizophrenia. Schizophrenia Bulletin, 1991. 17(3): 453–459.
   Google Scholar
• Guest, JF, Hart, WM, Cookson, RF, et al., Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. British Journal of Medical Economics, 1996. 10: 59–67.
   Google Scholar
• Davies, LM, Drummond, MF, Economics and schizophrenia: the real cost. British Journal of Psychiatry, 1995. 165(25): 18–21.
   Google Scholar
• Knapp, M, Beecham, J, Anderson, J, et al., The TAPS project. 3. Predicting the community costs of closing psychiatric hospitals. British Journal of Psychiatry, 1990. 157: 661 – 670.
   PubMed Web of Science ®Google Scholar
• Knapp, M, Chisholm, D, Astin, J, et al., The cost consequences of changing the hospital-community balance: the mental health residential care study. Psychological Medicine, 1997’. 27(3):681 – 692.
   Google Scholar
• Gray, AM, Marshall, M, Lockwood, A, et al., Problems in conducting economic evaluations alongside clinical trials: Lessons from a study of case management for people with mental disorders. British Journal of Psychiatry, 1997. 170: 47 – 52.
   PubMed Web of Science ®Google Scholar
• Lindstrom, E, Eriksson, B, Hellgren, A, et al., Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clinical Therapeutics, 1995. 17(3): 402–412.
   PubMedGoogle Scholar
• Hart, WM, Lindstrom, E, Guest, JF, Economic impact of the use of risperidone for the treatment of chronic schizophrenia in Ireland. Irish Journal of Psychiatry, 1997(Spring/Summer): 12 – 16.
   Google Scholar
• Viale, G, Mechling, L, Maislin, G, et al., Impact of risperidone on the use of health care resources. Psychiatric Services, 1997’. 48(9):1153 -1159.
   Google Scholar
• Albright, PS, Livingstone, S, Keegan, DL, et al., Reduction of Healthcare Resource Utilisation and Costs Following the Use of Risperidone for Patients with Schizophrenia Previously Treated with Standard Antipsychotic Therapy. Clinical Drug Investigation, 1996. 11(5): 289–299.
   Google Scholar
• Albright, P, Livingstone, S, Keegan, D, et al. Long-term health care resource utilisation and costs before and after initiation of risperidone treatment in patients with chronic schizophrenia. American Psychiatric Association. May 1997.
   Google Scholar
• Drummond, M, Economic analysis alongside clinical trials; an introduction for clinical reseachers, 1994, NHS R& D Directorate and Centre for Health Economics: Leeds & York.
   Google Scholar
• Cohen, LJ, Looking beyond the formulary budget in cost-benefit analysis. American Journal of Managed Care, 1997’. 3: S11 -S17.
   Google Scholar
• Maynard, AL, Cookson, RF, Computer Modelling: The need for careful evaluation and public audit. Pharmacoeconomics (submitted), 1998.
   Google Scholar
• Davies, A, Langley, PC, Keks, NA, et al., Risperidone vesus Haloperidol: II. Cost-effectiveness. Clinical Therapeutics, 1998. 20(1): 196 – 213.
   PubMed Web of Science ®Google Scholar
• Overall, JE, Gorham, DR, The Brief Psychiatric Rating Scale. Psychological Reports, 1962. 10: 799–812.
   Google Scholar
• Kay, SR, Opler, LA, Lindenmayer, J-P, The positive and negative syndrome scale (PANSS) rationale and standardisation. British Journal of Psychiatry, 1989. 155(Suppl 7): 59–65.
   Google Scholar
• Bell, M, Nilstein, R, Beam-Goulet, J, et al., The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale: reliability, comparability and predictive validity. Journal of Nervous and Mental Disease, 1992. 180(11): 723–728.
   PubMed Web of Science ®Google Scholar
• Song, F, Risperidone in the treatment of schizophrenia: a meta-analysis of randomised controlled trials. Journal of Clinical Psychopharmacology, 1997’. 11(1): 65–71.
   Google Scholar
• Rawlins, MD, Jefferys, DB, United Kingdom Product Licence applications inolving new active substances, 1987-1989: their fate after appeals. British Journal of Clinical Pharmacology, 1993. 35: 599 – 602.
   PubMedGoogle Scholar
• Fitton, A, Benfield, P, Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. Pharmacoeconomics, 1993. 4(2): 131–156.
   PubMedGoogle Scholar
• Torrance, GW, Feeny, D, Utilities and quality-adjusted life years. International Journal of Technology Assessment in Health Care, 1989. 5: 559 – 575.
   Google Scholar
• Williams, A, Economics, QALYs and medical ethics: a health economist’s perspective, 1994, University of York, Centre for Health Economics: York,UK.
   Google Scholar
• Laupacis, A, Feeny, D, Detsky, AS, et al., How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal, 1992. 146(4): 473 – 481.
   PubMed Web of Science ®Google Scholar
• Chouinard, G, Albright, P, Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology, 1997. 17(4): 298–307.
   Google Scholar
• Janssen, PAJ, Niemegeers, CJE, Awouters, F, et al., Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonist properties. Journal of Pharmacology and Experimental Therapeutics, 1988. 244: 685–693.
   PubMed Web of Science ®Google Scholar
• Johnstone, EC, et al, Schizophrenia: problems in clinical practice. Lancet, 1993. 341: 536 – 538.
   PubMed Web of Science ®Google Scholar
• Schotte A, Van Baelen B, Treatment of the symptoms of schizophrenia: a meta-analysis comparing Risperidone with other antipsychotic agents. Poster presented at the 9th Biennial Winter Workshop on Schizophrenia, February 7-13, 1998, Davos, Switzerland; Amery W, Zuiderwijk P, Lemmens P and Van Baelen B, Safety profile of Risperidone. Presented at the 10th European College of Neuropsychopharmacology Congress, Vienna, Austria, September 13-17, 1997.
   Google Scholar
• Davies, A, Adena, MA, Keks, NA, et al., Risperidone versus Haloperidol: I. Metaanalysis of Efficacy and Safety. Clinical Therapeutics, 1998. 20(1): 58 – 71.
   PubMedGoogle Scholar
• Chouinard, G, Ross-Chouinard, A, Annable, L, et al., The Extrapyramidal Symptom Rating Scale. Canadian Journal of Neurological Sciences, 1980. 7(3): 233.
   Web of Science ®Google Scholar
• Heinrich, K, Kleiser, E, Lehmann, E, et al. Experimental comparison of the efficacy and compatibility of risperidone and clozapine in acute schizophrenia. 17th Congress of Collegium Internationale Neuro-Psychopharmacologicum. 1990. Kyoto, Japan.
   Google Scholar
• Barcia, D, Ayuso, JL, Herraiz, ML, et al., Calidad de vida en pacientes esquizofrenicos tratados con risperidona. Anales de Psiquiatria, 1996. 12(10): 403–412.
   Google Scholar
• Addington, DE, Jones, B, Bloom, D, et al., Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clinical Therapeutics, 1993. 15(5): 917–926.
   PubMedGoogle Scholar
• Strand, L, Downey, W, Health databases in Saskatchewan. Pharmacoepidemiology, ed. B. Strom. 1994, John Wiley and Sons Ltd: West Sussex UK.
   Google Scholar
• Le Lorier, J, Petersen, T, Albright, PS. A retrospective cohort study of the RAMQ database to study the impact of risperidone use in the province of Quebec. Canadian Psychiatric Association. 1997.
   Google Scholar
• Le Lorier, J. Effect of risperidone on health care resource use in Quebec. APA. September 1997.
   Google Scholar
• Finley, PR, Corbitt, JL, Brunsen, GH, et al. Patient outcome analysis of risperidone treatment. Annual Meeting of the American College of Clinical Pharmacy. August 1996. Nashville TN.
   Google Scholar
• Thompson, D, Cost of switching from neuroleptics to risperidone and clozapine; a pilot study of the San Diego County Mental Health Services. Clinical Drug Investigation, 1997’. 14: 428–433.
   Google Scholar
• Chouinard, G, Jones, B, Remington, G, et al., A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 1993. 13(1): 25–40.
   PubMed Web of Science ®Google Scholar